Episode
Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers
- Podcast
- The IMID Forum
- Published
- Mar 19, 2026
- Duration seconds
- 2009
- Processing state
not_requested- Canonical source
- https://soundcloud.com/imidforum/discussing-axspa-symptom
Actions
POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-axspa-symptom-duration-impact-on-bimekizumab-efficacy-and-therapeutic-switching-drivers/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-symptom-duration-impact-on-bimekizumab-efficacy-and-therapeutic-switching-drivers.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.